Pacira Pharmaceuticals, Inc. (PCRX)

[surf1944]

6:31AM Pacira Pharma announced new data supporting use of EXPAREL via Infiltration into the Transversus Abdominis Plane; 100% of the available subjects reported being either satisfied or extremely satisfied with their postsurgical pain control (PCRX) 15.89 : Twenty-four patients undergoing robotic prostatectomy were enrolled in this open-label, prospective study to evaluate the efficacy and safety of EXPAREL via TAP infiltration. Key findings include:

Patients required a mean of less than one oxycodone/acetaminophen tablet per day from their discharge until their day 10 visit.
100 percent of the available subjects reported being either satisfied or extremely satisfied with their postsurgical pain control at hospital discharge, at 72 hours and on day 10.
When retrospectively compared to a 2011 study of patients who received a TAP infiltration of bupivacaine HCl, patients administered EXPAREL in the same fashion had similar or better pain scores with a reduced requirement for opioids.
There were no treatment-related adverse events in the study.
EXPAREL is indicated for single-dose administration into the surgical site to produce postsurgical analgesia.